Patients with aggressive non-Hodgkin lymphoma with positive interim F-18 FDG-PET scans and continued rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment had similar two-year event-free survival as those who switched to the Burkitt protocol, while those with negative PET scans who continued R-CHOP had a 76.4% EFS rate, compared with 73.5% for those who took R-CHOP with two additional rituximab doses, researchers reported in the Journal of Clinical Oncology. The findings suggest that interim PET may differentiate lymphomas sensitive to and resistant to chemotherapy, but PET-based treatment intensification may not boost outcomes.
Interim FDG-PET evaluated in predicting non-Hodgkin lymphoma survival
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.